UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE

ACT OF 1934

For the quarterly period ended ~~August~~November 3130, 2025

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT OF 1934

Commission File Number: 000-54500

Stimcell Energetics Inc.

(Exact name of registrant as specified in its charter)

Nevada		38-3939625
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1130 Pender Street, West, Suite 820 Vancouver, British Columbia		V6E 4A4
1130 Pender Street, West, Suite 555 Vancouver, British Columbia		V6E 4A4
(Address of principal executive offices)		(Zip code)

(844) 238-2692

(Registrant’s telephone number, including area code)

~~N/A~~1130 Pender Street, West, Suite 820, Vancouver, British Columbia V6E 4A4

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller Reporting Company ☒
		Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of ~~October~~January 1415, ~~2025~~2026, was 20,~~641~~891,272.

CONTENTS

PART I - FINANCIAL INFORMATION	1
Item 1. Financial Statements	1
Item 2. Management ’s Discussion and Analysis of Financial Condition and Results of Operations	2
Item 3. Quantitative and Qualitative Disclosure about Market Risk	5
Item 4. Controls and Procedures	5
PART II - OTHER INFORMATION	7
Item 1. Legal Proceedings	7
Item 1A. Risk Factors	7
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	12
Item 3. Defaults upon Senior Securities	12
Item 4. Mine Safety Disclosures	12
Item 5. Other Information	12
Item 6. Exhibits	13
SIGNATURES	16

iii

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

The accompanying unaudited condensed consolidated financial statements of Stimcell Energetics Inc. as at ~~August~~November 3130, 2025, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ deficit in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

Operating results for the three and six months ended ~~August~~November 3130, 2025, are not necessarily indicative of the results that can be expected for the year ending May 31, 2026.

As used in this Quarterly Report, the terms “we,” “us,” “our,” “Stimcell,” “Stimcell Energetics,” and the “Company” mean Stimcell Energetics Inc. and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.

STIMCELL ENERGETICS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	August 31, 2025		May 31, 2025
	November 30, 2025		May 31, 2025
ASSETS
Current assets
Cash	$	646,~~437~~159	$	14,581
Other current assets		96,~~950~~186		6,641
Total assets	$	1652,~~387~~345	$	21,222
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Liabilities
Accounts payable	$	~~296~~323,~~001~~867	$	322,144
Accrued liabilities		3815,~~694~~402		26,954
Due to related parties		~~493~~546,~~628~~447		448,536
Notes and advances due to related parties		~~582~~708,~~013~~923		469,874
Total liabilities		1,~~410~~594,~~336~~639		1,267,508
STOCKHOLDERS’ DEFICIT
Common stock, $0.001 par value, 500,000,000 shares authorized; 20,516,272 and 20,141,272 shares issued and outstanding at August 31, 2025 and May 31, 2025, respectively		20,516		20,141
Common stock, $0.001 par value, 500,000,000 shares authorized; 20,891,272 and 20,141,272 shares issued and outstanding at November 30, 2025 and May 31, 2025, respectively		20,891		20,141
Additional paid-in capital		9,~~266~~395,~~216~~841		9,146,591
Reserves		366,493		366,493
Accumulated deficit		(11,~~127~~436,~~158~~906)		(10,861,556)
Accumulated other comprehensive income		79111,~~984~~387		82,045
Total stockholders’ deficit		(1,~~393~~542,~~949~~294)		(1,246,286)
Total liabilities and stockholders’ deficit	$	1652,~~387~~345	$	21,222

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-1

STIMCELL ENERGETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	Three Months Ended August 31,
	Three Months Ended November 30,				Six Months Ended November 30,
	2025		2024			2025		2024
Operating expenses
Consulting fees	$	34,~~830~~365	$	34,~~894~~743		$	69,195	$	69,637
Foreign exchange gain		(1,769)		(14,209)
Foreign exchange		21,548		50,774			19,779		36,565
General and administrative expenses		~~139~~163,~~484~~598		1622,~~451~~681			303,082		39,132
Management fees		22,500		22,500			45,000		45,000
Research and development costs		5751,~~309~~035		-			108,344		-
Total operating expenses		~~252~~293,~~354~~046		59130,~~636~~698			545,400		190,334
Other items
Forgiveness of debt		-		~~1,569~~-			-		1,569
Interest		(1316,~~248~~702)		(8,~~852~~810)			(29,950)		(17,662)
Net loss		(~~265~~309,~~602~~748)		(66139,~~919~~508)			(575,350)		(206,427)
Foreign currency translation		(231,~~061)~~403		~~(18~~65,~~521)~~533			29,342		47,012
Comprehensive loss	$	(~~267~~278,~~663~~345)	$	(8573,~~440~~975)		$	(546,008)	$	(159,415)
Net loss per common share
Basic and diluted	$	(0.01)	$	(0.0001)		$	(0.03)	$	(0.01)
Weighted average number of shares outstanding
Basic and diluted		20,~~319~~692,~~261~~096		19,~~815~~816,~~758~~272			20,504,660		19,816,272

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-2

STIMCELL ENERGETICS INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	Common Stock
	Shares	Amount		Additional Paid-in Capital		Reserves		Deficit Accumulated		Accumulated Other Comprehensive Income		Total
Balance - May 31, 2024	19,816,272	$	19,816	$	9,013,501	$	366,493	$	(10,295,263)	$	68,998	$	(826,455)
Debt forgiven by shareholders	-		-		3,165		-		-		-		3,165
Net loss for the period ended Aug. 31, 2024	-		-		-		-		(66,919)		-		(66,919)
Translation to reporting currency	-		-		-		-		-		(18,521)		(18,521)
Balance – August 31, 2024	19,816,272	$	19,816	$	9,016,666	$	366,493	$	(10,362,182)	$	50,477	$	(908,730)
Net loss for the period ended Nov. 30, 2024	-		-		-		-		(139,508)		-		(139,508)
Translation to reporting currency	-		-		-		-		-		65,533		65,533
Balance – November 30, 2024	19,816,272	$	19,816	$	9,016,666	$	366,493	$	(10,501,690)	$	116,010	$	(982,705)
Balance – May 31, 2025	20,141,272	$	20,141	$	9,146,591	$	366,493	$	(10,861,556)	$	82,045	$	(1,246,286)
Shares issued for service	375,000		375		119,625				-		-		120,000
Net loss for the period ended Aug. 31, 2025	-		-		-		-		(265,602)		-		(265,602)
Translation to reporting currency	-		-		-		-		-		(2,061)		(2,061)
Balance – August 31, 2025	20,516,272	$	20,516	$	9,266,216	$	366,493	$	(11,127,158)	$	79,984	$	(1,393,949)
Shares issued for service	375,000		375		129,625				-		-		130,000
Net loss for the period ended Nov. 30, 2025	-		-		-		-		(309,748)		-		(309,748)
Translation to reporting currency	-		-		-		-		-		31,403		31,403
Balance – November 30, 2025	20,891,272	$	20,891	$	9,395,841	$	366,493	$	(11,436,906)	$	111,387	$	(1,542,294)

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-3

STIMCELL ENERGETICS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	Three Months Ended August 31,
	Six Months Ended November 30,
	2025		2024
Cash flows used in operating activities
Net loss	$	(~~265~~575,~~602~~350)	$	(66206,~~919~~427)
Adjustments to reconcile net loss to net cash used in operating activities
Accrued interest on notes payable		1127,~~978~~035		714,~~006~~239
Accrued interest on vendor payables		12,~~270~~915		13,~~846~~423
Gain on forgiveness of debt		-		(1,569)
Non-cash investor relations fees		~~120~~250,000		-
Unrealized foreign exchange		~~(514)~~19,477		~~(14~~36,~~523)~~041
Changes in operating assets and liabilities
Other current assets		~~(3,307)~~435		~~875~~(1,886)
Accounts payable		~~(27,482)~~978		2028,~~702~~361
Accrued liabilities		(11,~~739~~529)		(2115,~~361~~699)
Due to related parties		43103,~~776~~759		51104,~~026~~081
Net cash flows used in operating activities		(~~108~~182,~~142~~280)		(2239,~~917~~436)
Cash flows from financing activities
Proceeds from notes due to related parties		~~100~~214,~~000~~248		-30,000
Net cash provided by financing activities		~~100~~214,~~000~~248		-30,000
Effects of foreign currency exchange on cash		(2390)		54(158)
Decrease in cash		(8,144)		(22,863)
Change in cash		31,578		(9,594)
Cash, beginning		14,581		43,415
Cash, ending	$	646,~~437~~159	$	2033,~~552~~821

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-4

STIMCELL ENERGETICS INC.

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

~~AUGUST~~NOVEMBER 3130, 2025

(Unaudited)

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Stimcell Energetics Inc. (“Stimcell”, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”, or the “Subsidiary”) under the laws of the province of British Columbia. Stimcell is a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness.

Effective November 1, 2024, the Company completed a 1-for-15 reverse split (the “Reverse Split”) of its common stock. As a result of the Reverse Split, the Company’s authorized capital was decreased from 7,500,000,000 shares of common stock with par value of $0.001, of which 297,236,373 shares were outstanding immediately prior to the Reverse Split, to 500,000,000 shares of common stock with par value of $0.001. All share and per-share amounts in these unaudited interim condensed consolidated financial statements have been retrospectively adjusted.

Concurrent with the Reverse Split, the Company amended its articles of incorporation to change the Company’s name from “Cell MedX Corp.” to “Stimcell Energetics Inc.”

Unaudited Interim Financial Statements

The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all the information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2025, included in the Company’s Annual Report on Form 10-K, filed with the SEC on September 2, 2025. The interim unaudited condensed consolidated financial statements for the three and six months ended ~~August~~November 3130, 2025, should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six months ended ~~August~~November 3130, 2025, are not necessarily indicative of the results that may be expected for the year ending May 31, 2026.

Going ~~concern~~Concern

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of ~~August~~November 3130, 2025, the Company has not achieved profitable operations and has accumulated a deficit of $11,~~127~~436,~~158~~906. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.

Earnings (Loss) Per Share

Basic and diluted loss per share are computed in accordance with ASC 260. Basic loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution from common share equivalents (e.g., warrants) using the treasury stock method; however, for the periods presented, the effect of such instruments was anti-dilutive, and therefore diluted loss per share is the same as basic loss per share.

F-5

The following table presents the calculation of the loss per share:

	Three months ended August 31,
	Three months ended November 30,				Six months ended November 30,
	2025		2024		2025		2024
Net loss attributable to common shareholders	$	~~265~~309,~~602~~748	$	$139,508	~~66,919~~$	575,350	$	206,427
Weighted-average common shares outstanding		20,~~319~~692,~~261~~096		19,816,272	~~19,815,758~~	20,504,660		19,816,272
Loss per common share (basic and diluted)	$	0.01	$	$0.01	~~0.00~~$	0.03	$	0.01

All per-share amounts and share counts have been retroactively adjusted to reflect the 1-for-15 reverse stock split effective November 1, 2024.

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than advances and notes payable to related parties (Note 3) at ~~August~~November 3130, 2025, and at May 31, 2025:

	August 31, 2025		May 31, 2025
	November 30, 2025		May 31, 2025
Due to the Chief Executive Officer (“CEO”) and President	$	~~165~~196,~~912~~988	$	144,237
Due to the Chief Financial Officer (“CFO”)		5,~~500~~615		8,778
Due to an entity controlled by a director of the Company		~~322~~343,~~216~~844		295,521
Due to related parties(1)	$	~~493~~546,~~628~~447	$	448,536

(1)The amounts due to related parties are unsecured, due on demand and bear no interest.

During the ~~three~~six months ended ~~August~~November 3130, 2025 and 2024, the Company had the following transactions with related parties:

	August 31, 2025		August 31, 2024
	November 30, 2025		November 30, 2024
Management fees incurred to the CEO and President	$	2245,~~500~~000	$	2245,~~500~~000
Consulting fees incurred to the CFO		715,~~500~~000		715,~~500~~000
Consulting fees incurred to an entity controlled by a director of the Company		2754,~~330~~195		2754,~~394~~637
Total transactions with related parties	$	57114,~~330~~195	$	57114,~~394~~637

NOTE 3 - NOTES AND ADVANCES DUE TO RELATED PARTIES

The tables below summarize the loans and advances due and payable to related parties as at ~~August~~November 3130, 2025 and May 31, 2025:

As at August 31, 2025
As at November 30, 2025
Principal Outstanding		Interest Rate per Annum		Accrued Interest		Total Book Value
$	78,~~947~~033	6%	Related party loans payable (1)	$	2122,~~558~~817	$	100,~~505~~850
	411,854	10%	Related party loans payable (1)		58,739		470,593
	525,112	10%	Related party loans payable (1)		72,231		597,343
	10,915	0%	Advances(2)		-		10,915
	10,730	0%	Advances(2)		-		10,730
$	~~501~~613,~~716~~875			$	8095,~~297~~048	$	~~582~~708,~~013~~923
As at May 31, 2025
Principal Outstanding		Interest Rate per Annum		Accrued Interest		Total Book Value
$	78,884	6%	Related party loans payable (1)	$	20,038	$	98,923
	311,782	10%	Related party loans payable (1)		48,267		360,049
	10,902	0%	Advances(2)		-		10,902
$	401,568			$	68,305	$	469,874

F-6

(1) Related Party Loans Payable

As at ~~August~~November 3130, 2025, the Company owed a total of $100,~~505~~850 under 6% notes payable due to related parties (May 31, 2025 - $98,923), of which $2122,~~558~~817 was associated with interest accrued on the principal balances owed under the notes payable (May 31, 2025 - $20,038).

As at ~~August~~November 3130, 2025, the Company owed a total of $~~470~~597,~~593~~343 under 10% notes payable due to related parties (May 31, 2025 - $360,049), of which $5872,~~739~~231 was associated with interest accrued on the principal balances owed under the notes payable (May 31, 2025 - $48,267).

Notes payable with Mr. Richard Jeffs

During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company borrowed $~~100~~200,000 from Mr. Richard Jeffs under a non-secured credit line, which allows the Company to draw up to USD$200,000 at 10% per annum and is payable on demand.

As at ~~August~~November 3130, 2025, the Company owed a total of $~~197~~301,~~394~~666 (May 31, 2025 - $66,693) to Mr. Richard Jeffs, a significant shareholder of the Company and the father of the Company’s CEO and President, Mr. David Jeffs. A total of $67,~~786~~639 (including accrued interest of $1314,~~837~~606) was borrowed under unsecured notes payable, which accrue interest at a rate of 6% per annum, compounded monthly, and are due on demand. The remaining amount of $~~129~~234,~~608~~027 was borrowed under unsecured credit lines, which allow the Company to draw up to CAD$100,000 and up to US$200,000 at 10% per annum, compounded monthly and payable on demand.

During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company recorded $38,~~034~~938 in interest on the notes payable and the funds borrowed under the credit lines with Mr. Richard Jeffs (~~August~~November 3130, 2024 - $~~960~~1,918).

Notes payable with Mr. David Jeffs

As of ~~August~~November 3130, 2025, the Company owed a total of $4849,~~837~~891 under loan agreements with Mr. David Jeffs, the Company’s CEO, director, and a significant shareholder (May 31, 2025 - $47,615). The loans accrue 10% annual interest, compounded monthly, are unsecured, and are payable on demand. The $30,000 loan was payable on April 24, 2023, and is therefore in default as of the date of these condensed consolidated financial statements. During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company recorded $12,~~211~~435 in interest on the principal (~~August~~November 3130, 2024, $12,~~080~~173).

As of ~~August~~November 3130, 2025, the Company owed a total of $3233,~~719~~211 under a loan agreement with a company of which Mr. David Jeffs is a director (May 31, 2025 - $32,229). The loan bears interest at 6% per annum compounded monthly, is unsecured, and is payable on demand. During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company recorded $~~490~~982 in interest on the principal (~~August~~November 3130, 2024 - $~~461~~925).

Notes payable with Mr. Amir Vahabzadeh

As at ~~August~~November 3130, 2025, the Company owed a total of $~~190~~194,~~007~~784 under loan agreements with Mr. Vahabzadeh, a director and a significant shareholder (May 31, 2025 - $185,297). The loans are unsecured and carry a 10% annual interest rate, compounded monthly. A $30,000 note payable included in the total due was payable on April 24, 2023, and, as of the date of these condensed consolidated financial statements, is in default. The remaining notes payable, totaling $130,000, are payable on demand. During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company recorded $49,~~710~~486 in interest on the principal (~~August~~November 3130, 2024 - $25,~~831~~851).

Notes payable with a significant shareholder

As at ~~August~~November 3130, 2025, the Company owed $7476,~~605~~481 (May 31, 2025 - $72,756) under unsecured notes payable with the Company’s significant shareholder (“Mr. Ahdoot”). The loans are unsecured and carry a 10% annual interest rate, compounded monthly. During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company recorded $13,~~849~~725 in interest on the principal (~~August~~November 3130, 2024 - $13,~~674~~372).

F-7

Notes payable with Mrs. Susan Jeffs

AsDuring atthe ~~August~~six 31months ended November 30, 2025, the Company ~~owed~~borrowed $2714,~~536~~248 ~~(May~~from ~~31, 2025 - $26,822) under non-secured credit line with~~ Mrs. Susan Jeffs, mother of Mr. David Jeffs., ~~The~~under ~~terms~~a ofnon-secured ~~the~~ credit line, ~~allow~~which allows the Company to draw up to CAD$100,000 at 10% per annum and is payable on demand. ~~During the three months ended August 31, 2025, the Company recorded $684 in interest on the principal (August 31, 2024 - $Nil).~~

As at November 30, 2025, the Company owed $42,160 (May 31, 2025 - $26,822) under non-secured credit line with Mrs. Susan Jeffs. During the six months ended November 30, 2025, the Company recorded $1,469 in interest on the principal (November 30, 2024 - $Nil).

(2) Advances Payable

As at ~~August~~November 3130, 2025, the Company owed a total of $10,~~915~~730 (May 31, 2025 - $10,902) for an advance the Company received in its fiscal 2020 year from an entity controlled by Mr. David Jeffs. The advance is non-interest-bearing, unsecured, and payable on demand.

NOTE 4 - OTHER CURRENT ASSETS

As at ~~August~~November 3130, 2025, other current assets consisted of $6,~~700~~175 in prepaid expenses (May 31, 2025 - $3,400) and $~~3,250~~11 in receivables associated with GST Cell MedX Canada paid on taxable supplies (May 31, 2025 - $3,241).

NOTE 5 - SHARE CAPITAL

During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company issued ~~375~~750,000 shares valued at $~~120~~250,000, under an agreement with an investor relations and public relations firm to provide services for an eight-month term, which commenced on March 18, 2025. The total fair value of these shares was recognized as part of corporate communications fees included in general and administrative expenses.

Options

As at ~~August~~November 3130, 2025 and May 31, 2025, the Company did not have any share purchase options issued and exercisable.

Warrants

The changes in the number of warrants outstanding during the ~~three~~six months ended ~~August~~November 3130, 2025, and for the year ended May 31, 2025, are as follows:

	Three months ended August 31, 2025			Year ended May 31, 2025
	Six months ended November 30, 2025			Year ended May 31, 2025
	Number of warrants	Weighted average exercise price		Number of warrants	Weighted average exercise price
Warrants outstanding, beginning	166,667	$	0.75	166,667	$	0.75
Warrants issued	-	$	-	-	$	-
Warrants outstanding, ending	166,667	$	0.75	166,667	$	0.75

All warrants outstanding at ~~August~~November 3130, 2025, are exercisable at $0.75 and expire on March 12, 2026.

NOTE 6 - RESEARCH AND DEVELOPMENT

In February 2025, the Company recommenced the work on redesigning its eBalance® microcurrent device under a new partnership with ADM Tronics Unlimited, Inc (“ADM Tronics”). The Company ~~expects~~expected the project to take approximately 22 to 34 weeks and to cost between $62,500 and $127,000. ~~During~~As ~~the~~of ~~three~~November ~~months ended August 31~~30, 2025, the ~~Company had incurred $57,309 on this~~ project. Ashas ofnot ~~August~~been 31completed, ~~2025,~~and the Company ~~had~~continues ~~spent~~to awork ~~total~~with ofADM ~~$121~~Tronics,~~318~~ ~~since~~at ~~the~~a ~~project~~regular ~~began~~hourly fee.

During the six months ended November 30, 2025, the Company had incurred $108,344 on this project. As of November 30, 2025, the Company had spent a total of $172,353 since the project began.

F-8

NOTE 7 - SUBSEQUENT EVENT

Subsequent to August 31, 2025, the Company issued 125,000 common shares under an agreement with an investor relations and public relations firm to provide services for an eight-month term, which commenced on March 18, 2025. These shares were valued at $33,750 (Note 5).

In September of 2025, the Company borrowed an additional $50,000 from Mr. Richard Jeffs under a non-secured credit line, which allows the Company to draw up to USD$200,000 at 10% per annum and is payable on demand. As of the date of this Quarterly Report on Form 10-Q, the Company had borrowed a total of $150,000 under the credit line (Note 3).

F-9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of the Company’s financial condition and results of operations should be read in conjunction with the Company’s unaudited condensed consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the “Risk Factors” in Part II, Item 1A of this Quarterly Report.

The discussion provided in this Quarterly Report should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended May 31, 2025, filed with the United States Securities and Exchange Commission (the “SEC”) on September 2, 2025.

Overview

The Company was incorporated under the laws of the State of Nevada on March 19, 2010. On April 26, 2016, the Company formed a wholly owned subsidiary, Cell MedX (Canada) Corp., (“Cell MedX Canada”, or the “Subsidiary”) under the laws of the Province of British Columbia.

Effective November 1, 2024, the Company completed a 1-for-15 reverse split (the “Reverse Split”) of its common stock. As a result of the Reverse Split, the Company’s authorized capital was decreased from 7,500,000,000 shares of common stock with par value of $0.001, of which 297,236,373 shares were outstanding immediately prior to the Reverse Split, to 500,000,000 shares of common stock with par value of $0.001, of which 19,816,272 were outstanding. All share and per-share amounts in this Quarterly Report on Form 10-Q have been retrospectively adjusted.

Concurrent with the Reverse Split, the Company amended its articles of incorporation to change the Company’s name from “Cell MedX Corp.” to “Stimcell Energetics Inc.” (the “Name Change”).

Stimcell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health, anti-aging, pain relief, wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, insulin resistance, high blood pressure, neuropathy and kidney function. Cell MedX (Canada) is engaged in development and manufacturing of therapeutic devices based on the proprietary eBalance® Technology, which harnesses the power of microcurrents and their effects on the human body.

Recent Corporate Developments

In February 2025, the Company announced a new partnership with ADM Tronics Unlimited, Inc. to redesign the Company’s proprietary eBalance® microcurrent device, transforming it into a compact, affordable consumer unit optimized for home use, complete with additional diagnostic features. The Company’s vision is to redesign its eBalance® to empower individuals to take control of their health from the comfort of home. The new version will be smaller and more cost-effective than its predecessors, making microcurrent technology accessible to a broader audience. Additionally, it will feature additional diagnostics, including a real-time assessment of cellular energy capacity, treatment tracking, and personalized user profiles.

On December 1, 2025, the Company entered into a service agreement with the St. Boniface Hospital Albrechtsen Research Centre, affiliated with the University of Manitoba, and Principal Investigator, Professor Paul Fernyhough, to explore the effects of eBalance® device on mitochondrial function in cultured sensory neurons to further define the physiological action of microcurrents.

Under the agreement, Dr. Fernyhough's team will conduct a series of experiments to assess how eBalance® stimulation influences key aspects of cellular energy production by mitochondria. Using established biological assays in Dr. Fernyhough's laboratory, the study will measure oxygen consumption rates (OCR) to evaluate impacts on the electron transport chain, ATP production, glycolysis, basal respiration, maximal respiration, spare respiratory capacity, coupling efficiency, and proton leak. Additional analyses will quantify enzyme activities such as AMP-activated protein kinase (AMPK) and levels of respiratory proteins through Western blotting. The project, expected to span approximately three months, involves acute and longer-term stimulation of dissociated adult rat dorsal root

~~Results~~ganglia of(DRG) ~~Operations~~neurons ~~for~~under ~~the~~controlled ~~Three~~conditions. ~~Months~~Replicates ~~ended~~will ~~August~~ensure 31robust statistical analysis, ~~2025~~with ~~and~~a ~~2024~~comprehensive report provided at the study's conclusion.

~~Operating~~Results ~~results~~of Operations for the ~~three~~Three ~~months~~and Six Months ended ~~August~~November 3130, 2025 and 2024~~, and the changes in the operating results between those periods are summarized in the table below.~~

	Three Months ended August 31,					Percentage Increase/ (Decrease)
	2025		2024
Operating expenses
Consulting fees	$	34,830		$	34,894	(0.2)%
Foreign exchange gain		(1,769)			(14,209)	(87.6)%
General and administrative expenses		139,484			16,451	747.9%
Management fees		22,500			22,500	0.0%
Research and development costs		57,309			-	n/a
Total operating expenses		(252,354)			(59,636)	323.2%
Gain on forgiveness of debt		-			1,569	(100.0)%
Interest		(13,248)			(8,852)	49.7%
Net loss	$	(265,602)		$	(66,919)	296.9%

Operating results for the three and six months ended November 30, 2025 and 2024, and the changes in the operating results between those periods are summarized in the table below.

	Three Months ended November 30,					Percentage Increase/ (Decrease)	Six Months ended November 30,				Percentage Increase/ (Decrease)
	2025		2024			Percentage Increase/ (Decrease)	2025		2024		Percentage Increase/ (Decrease)
Operating expenses
Consulting fees	$	34,365		$	34,743	(1.1)%	$	69,195	$	69,637	(0.6)%
Foreign exchange loss		21,548			50,774	(57.6)%		19,779		36,565	(45.9)%
General and administrative expenses		163,598			22,681	621.3%		303,082		39,132	674.5%
Management fees		22,500			22,500	-%		45,000		45,000	-%
Research and development costs		51,035			-	n/a		108,344		-	n/a
Total operating expenses		293,046			130,698	124.2%		545,400		190,334	186.5%
Gain on forgiveness of debt		-			-	n/a		-		(1,569)	(100.0)%
Interest		16,702			8,810	89.6%		29,950		17,662	69.6%
Net loss	$	309,748		$	139,508	122.0%	$	575,350	$	206,427	178.7%

Revenues

The Company did not have any revenue-generating activities during the three and six months ended ~~August~~November 3130, 2025 and 2024.

Operating Expenses

During the three months ended ~~August~~November 3130, 2025, the Company’s operating expenses increased by ~~323~~124.2% from $59130,~~636~~698 the Company incurred during the three months ended ~~August~~November 3130, 2024, to $~~252~~293,~~354~~046 incurred during the three months ended ~~August~~November 3130, 2025. The ~~most~~largest ~~significant~~change was associated with a $140,917 increase in general and administrative expenses, which increased from $22,681 the Company incurred during the three months ending November 30, 2024, to $163,598 during the three months ending November 30, 2025. The main driver of this change was a $134,362 increase in corporate communications, which rose to $135,137 in the current period from $775 in the same period last year. Other notable changes included a $10,560 increase in regulatory fees to $17,678 (November 30, 2024 - $7,118), a $2,008 increase in office expenses to $2,861 (November 30, 2024 - $853), and $1,330 in travel expenses, an expense the Company did not incur in the comparative period. These increases were aspartly ~~follows:~~offset by a $7,224 decrease in professional fees, from $7,469 during the comparative period to $245 during the current period ended November 30, 2025. All other expenses included in general and administrative fees remained relatively stable.

~~·General~~The ~~and~~second ~~administrative~~largest ~~expenses~~change ~~for~~was ~~the~~associated ~~three~~with ~~months ending August 31, 2025, increased by~~ $~~123~~51,~~033,~~035 orin ~~747.9%,~~research ~~from~~and ~~$16,451~~development ~~during~~fees ~~the~~for ~~three months ending August 31, 2024, to $139,484 during~~ the three months ~~ending~~ended ~~August~~November 3130, 2025. The ~~main~~research ~~driver~~and ofdevelopment ~~this~~fees ~~change~~during ~~was a $114,854 increase in corporate communications, which rose to $119,224 in~~ the current period ~~from~~were ~~$4,370~~associated inwith the ~~same~~Company’s ~~period~~decision ~~last~~to ~~year.~~redesign ~~Other~~the ~~notable~~eBalance® ~~changes~~Home ~~included~~device into a $5compact,~~743~~ ~~rise~~affordable inconsumer ~~accounting~~unit ~~and~~optimized ~~audit~~for ~~fees,~~home ~~totaling $10~~use,~~211~~ ~~(August~~which ~~31,~~resulted ~~2024 - $4,468), and a $3,583 increase~~ in ~~regulatory~~an ~~fees~~engagement toof ~~$7,595~~ADM ~~(August~~Tronics 31Unlimited, ~~2024 - $4,012)~~Inc. ~~These~~During ~~increases~~the ~~were~~comparative ~~partly~~three ~~offset~~months byended aNovember $130,~~457~~ ~~decrease~~2024, inthe ~~professional~~development ~~fees,~~of ~~from~~the ~~$2,653~~eBalance® ~~during~~devices ~~the~~was ~~comparative~~suspended ~~period~~due to ~~$1,196~~a ~~during~~lack ~~the~~of ~~current~~funding ~~period~~and ~~ended~~unfavorable ~~August~~financial 31position, ~~2025.~~and ~~All~~therefore ~~other~~the ~~expenses~~Company ~~included~~had inno ~~general~~expenses ~~and~~associated ~~administrative~~with ~~fees~~research ~~remained~~and ~~relatively stable~~development.

·The ~~Company~~above ~~incurred~~increases ~~$57,309~~were in ~~research~~part ~~and~~offset ~~development~~by ~~fees for the three months ended August 31, 2025. The research and development fees during the current period were associated with the Company’s decision to redesign the eBalance® Home device into~~ a ~~compact~~$29,226 ~~affordable~~decrease ~~consumer unit optimized for home use, which resulted~~ in anforeign ~~engagement~~exchange ~~of ADM Tronics Unlimited~~loss, ~~Inc.,~~driven by a ~~leader~~weakening inCanadian ~~electronic~~dollar ~~medical~~relative ~~device~~to ~~engineering, who started working on~~ the ~~project~~U.S. indollar. ~~February~~As of ~~2025.~~November ~~During the comparative three months ended August 31~~30, ~~2024~~2025, the ~~development~~Company ofrecognized ~~the~~a ~~eBalance®~~foreign ~~devices~~exchange ~~was~~loss ~~suspended due to a lack~~ of ~~funding~~$21,548, ~~and~~compared ~~unfavorable~~with ~~financial position~~$50,774 ~~and~~during ~~therefore~~ the ~~Company~~same ~~had~~period noin ~~expenses associated with research and development~~2024.

~~·Foreign~~Along ~~exchange~~with ~~gain~~the ~~decreased~~changes byin ~~$12,440~~operating toexpenses amentioned ~~gain of $1~~above,~~769~~ ~~for~~ the ~~three~~Company ~~months~~also ~~ended~~incurred ~~Augus 31~~$22,500 ~~2025,~~in asmanagement ~~compared~~fees toand ~~a gain of~~ $1434,~~209~~365 ~~for~~in ~~the~~consulting ~~comparative~~fees, ~~period~~which ~~ended~~remained ~~August~~consistent ~~31,~~with ~~2024.~~the ~~The~~amounts ~~foreign~~the ~~exchange~~Company ~~gain~~incurred ~~was~~for ~~associated~~the ~~with~~three ~~relatively~~months ~~stable~~ended ~~Canadian~~November ~~and~~30, ~~US currencies~~2024.

Along with the changes in operating expenses mentioned above, the Company also incurred $22,500 in management fees and $34,830 in consulting fees, which remained consistent with the amounts the Company incurred for the three months ended August 31, 2024.

On a year-to-date basis, the Company’s operating expenses increased by 186.5% from $190,334 the Company incurred during the six months ended November 30, 2024, to $545,400 the Company incurred during the six months ended November 30, 2025. The most significant changes were as follows:

·General and administrative expenses for the six months ending November 30, 2025, increased by $263,950, or 674.5%, from $39,132 during the six months ending November 30, 2024, to $303,082 during the six months ending November 30, 2025. The main driver of this change was a $249,216 increase in corporate communications, which rose to $254,361 in the current period from $5,145 in the same period last year. Other notable changes included a $14,143 increase in regulatory fees to $25,273 (November 30, 2024 - $11,130) and a $6,015 rise in accounting and audit fees to $16,211 (November 30, 2024 - $10,196). These increases were partly offset by an $8,681 decrease in professional fees, from $10,122 during the comparative period to $1,441 during the current period ended November 30, 2025. All other expenses included in general and administrative fees remained relatively stable.

·The Company incurred $108,344 in research and development fees for the six months ended November 30, 2025. The research and development fees during the current period were associated with the Company’s decision to redesign the eBalance® Home device into a compact, affordable consumer unit optimized for home use, which resulted in an engagement of ADM Tronics Unlimited, Inc. During the comparative six months ended November 30, 2024, the development of the eBalance® devices was suspended due to a lack of funding and unfavorable financial position, and therefore the Company had no expenses associated with research and development.

·Foreign exchange loss decreased by $16,786 to a loss of $19,779 for the six months ended November 30, 2025, as compared to a loss of $36,565 for the comparative period ended November 30, 2024. The foreign exchange loss was associated with a weakening Canadian dollar relative to the U.S. dollar.

Along with the changes in operating expenses mentioned above, the Company also incurred $45,000 in management fees and $69,165 in consulting fees, which remained consistent with the amounts the Company incurred for the six months ended November 30, 2024.

Other Items

During the three months ended ~~August~~November 3130, 2025, the Company accrued $1115,~~978~~057 (~~August~~November 3130, 2024 - $7,~~006~~233) in interest associated with outstanding notes payable to related parties and $1,~~270~~645 (~~August~~November 3130, 2024 - $1,~~846~~577) in interest accrued on other vendor payables. During the three months ended August 31, 2024, the Company discharged an outstanding debt to its vendors due to the balances exceeding the statute of limitations, which resulted in a gain on forgiveness of debt of $1,569. The Company did not have similar transactions during the three months ended August 31, 2025.

During the six months ended November 30, 2025, the Company accrued $27,035 (November 30, 2024 - $14,239) in interest on outstanding notes payable to related parties and $2,915 (November 30, 2024 - $3,423) in interest on other vendor payables. During the six months ended November 30, 2024, the Company discharged an outstanding debt to its vendors due to the balances exceeding the statute of limitations, which resulted in a gain on forgiveness of debt of $1,569. The Company did not have similar transactions during the six months ended November 30, 2025.

Liquidity and Capital Resources

Working Capital

	As at August 31, 2025		As at May 31, 2025		Percentage Increase/ (Decrease)
	As at November 30, 2025		As at May 31, 2025		Percentage Increase
Current assets	$	1652,~~387~~345	$	21,222	~~(22~~146.8)7%
Current liabilities		1,~~410~~594,~~336~~639		1,267,508	1125.38%
Working capital deficit	$	(1,~~393~~542,~~949~~294)	$	(1,246,286)	1123.8%

As of ~~August~~November 3130, 2025, the Company had a cash balance of $646,~~437~~159, a working capital deficit of $1,~~393~~542,~~949~~294, and cash flows used in operations of $~~108~~182,~~142~~280 for the period then ended. During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company funded its operations with $~~100~~214,~~000~~248 the Company borrowed from its related ~~party~~parties under a non-secured ~~line~~lines of credit at 10% annual interest compounded monthly and due on demand.

The Company did not generate sufficient cash flows from its operating activities to satisfy its cash requirements for the three months ended August 31, 2025. The amount of cash generated from the operations to date is significantly less than the Company’s current debt obligations. There is no assurance that the Company will be able to generate sufficient cash from operations to repay the amounts owing under the outstanding notes and advances payable, or to service other debt obligations. If the Company is unable to generate sufficient cash flow from operations to repay the amounts owing when due, it may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern.4

The Company did not generate sufficient cash flows from its operating activities to satisfy its cash requirements for the six months ended November 30, 2025. The amount of cash generated from the operations to date is significantly less than the Company’s current debt obligations. There is no assurance that the Company will be able to generate sufficient cash from operations to repay the amounts owing under the outstanding notes and advances payable, or to service other debt obligations. If the Company is unable to generate sufficient cash flow from operations to repay the amounts owed when due, it may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern.

Cash Flows

	Three months ended August 31,
	Six months ended November 30,
	2025		2024
Cash flows used in operating activities	$	(~~108~~182,~~142~~280)	$	(2239,~~917~~436)
Cash flows generated by financing activities		~~100~~214,~~000~~248		-30,000
Effects of foreign currency exchange on cash		(2390)		54(158)
Net decrease in cash during the period	$	(831,~~144)~~578	$	(229,~~863~~594)

Net Cash Used in Operating Activities

Net cash used in operating activities during the ~~three~~six months ended ~~August~~November 3130, 2025, was $~~108~~182,~~142~~280. This cash was primarily used to cover cash operating expenses of $~~132~~275,~~868~~923, which were represented by a net loss of $~~265~~575,~~602~~350, reduced by ~~the~~ non-cash items totaling $~~132~~299,~~734~~427, ~~to decrease accounts payable by $27,482,~~ and to ~~increase~~decrease ~~other~~accrued ~~current~~liabilities ~~assets, which include GST receivable and prepaid expenses~~ by $311,~~307~~529. These uses of cash were offset by a $43103,~~776~~759 increase in amounts due to related parties, a $978 increase in accounts payable, and ana $~~11,739~~435 ~~increase~~decrease in ~~accrued~~other ~~liabilities~~current assets, including GST receivable and prepaid expenses.

Net cash used in operating activities during the ~~three~~six months ended ~~August~~November 3130, 2024, was $2239,~~917~~436. This cash was primarily used to cover cash operating expenses of $74154,~~159~~293, which were represented by a net loss of $66206,~~919~~427 reduced by the non-cash items totaling $752,~~240~~134, ~~and~~ to decrease accrued liabilities by $2115,~~361~~699 and to increase other current assets by $1,886. These uses of cash were offset by a $51104,~~026~~081 increase in amounts due to related parties, and a $2028,~~702~~361 increase toin accounts payable~~, and an $875 decrease in other current assets, which include GST receivable and prepaid expenses~~.

Non-cash transactions

During the ~~three~~six months ended ~~August~~November 3130, 2025, net loss was affected by the following expenses that did not have any impact on cash used in operations:

·$~~120~~250,000 (~~August~~November 3130, 2024 - $Nil) in investor relations activities, which were paid for through the issuance of common shares;

·$1127,~~978~~035 (~~August~~November 3130, 2024 - $714,~~006~~239) in interest accrued on the outstanding notes due to related parties;

·$12,~~270~~915 (~~August~~November 3130, 2024 - $13,~~846~~423) in interest accrued on the vendor payables; and

·$~~514~~19,477 in unrealized foreign exchange ~~gain~~loss (~~August~~November 3130, 2024 - $1436,~~523~~041), which resulted from fluctuations of the Canadian dollar, the functional currency of Cell MedX Canada, in relation to the USU.S. dollar, the functional currency of the parent company, being also the Company’s reporting currency~~; and~~.

·During the comparative period ended ~~August~~November 3130, 2024, the Company recognized a $1,569 gain on forgiveness of debt, which was associated with the write-off of debt that exceeded the statute of limitations.

Net Cash Provided by Financing Activities

During the ~~three~~six months ended ~~August~~November 3130, 2025, the Company borrowed $~~100~~200,000 from Mr. Richard Jeffs, the Company’s major shareholder and the father of the Company’s CEO and President, Mr. David Jeffs, under a revolving credit line, which accumulates interest at 10% per annum compounded monthly and is due on demand. During the same period, the Company borrowed an additional $14,248 from Mrs. Susan Jeffs, the mother of the Company’s CEO and President, Mr. David Jeffs, under a revolving credit line that accrues interest at 10% per annum, compounded monthly, and is due on demand.

~~The Company did not have any financing activities during the three months ended August 31, 2024.~~5

During the six months that ended November 30, 2024, the Company borrowed $30,000 from its related party in exchange for a 10% note payable due on demand.

Net Cash Used in Investing Activities

The Company did not have any investing activities during the ~~three~~six months ended ~~August~~November 3130, 2025 and 2024.

Going Concern

The notes to the Company’s unaudited condensed consolidated financial statements as at ~~August~~November 3130, 2025, disclose an uncertain ability for the Company to continue as a going concern for the next twelve-month period. The Company’s current business operations are in an early development stage and as such, its ability to generate revenue from the operations is very minimal. The Company's research and development as well as marketing plans require large capital expenditures. Due to the financial difficulties the Company had faced, the research and development plans associated with the eBalance® technology were temporarily abandoned. In February 2025, the Company engaged ADM Tronics Unlimited, Inc., a leader in electronic medical device engineering, to redesign eBalance® microcurrent device, transforming it into a compact consumer unit, optimized for home use. ~~The project is expected to span approximately nine months.~~ Management is planning to support its operations as well as the redesign of the eBalance® microcurrent device through equity or debt financing.

As at ~~August~~November 3130, 2025, the Company had accumulated a deficit of $11,~~127~~436,~~158~~906 since inception and additional funding will be required to support the operations. The Company’s continuation as a going concern depends upon the continued financial support of its shareholders, its ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. The unaudited condensed consolidated interim financial statements do not give effect to any adjustments that would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the Company’s financial statements.

Off-Balance Sheet Arrangements

None.

Critical Accounting Policies

An appreciation of the Company’s critical accounting policies is necessary to understand its financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact the financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. The Company has applied its critical accounting policies and estimation methods consistently.

Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure

None.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

None

Item 4. Controls and Procedures

The Company’s management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that is designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of the Company’s management of the effectiveness of the design and operation of its disclosure controls and procedures as of August 31, 2025. Based on that evaluation, the Company’s management concluded that the disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.

During the quarter ended August 31, 2025, there were no changes in the internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

An evaluation was conducted under the supervision and with the participation of the Company’s management of the effectiveness of the design and operation of its disclosure controls and procedures as of November 30, 2025. Based on that evaluation, the Company’s management concluded that the disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.

During the quarter ended November 30, 2025, there were no changes in the internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There have been no material changes to the risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2025, filed with the Securities and Exchange Commission on September 2, 2025.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On March 18, 2025, the Company entered into a digital marketing services agreement (the “Agreement”) with Rain Communications Inc. (“Rain Communications”), pursuant to which, the Company committed to issue to Rain Communications a total of 1,000,000 shares at a deemed price of $0.20 per share over the eight-month service period ~~for a total consideration of $200,000~~. The shares ~~are~~were ~~being~~ issued in batches of 125,000 shares ~~each~~per month starting on April 18, 2025. The shares ~~are~~were ~~being~~ issued pursuant to provisions of Regulation S of the United States Securities Act of 1933, as amended (the “Act”) on the basis that Rain Communications is not a resident of the United States, and is otherwise not a “U.S. person” as that term is defined in Rule 902(k) of Regulation S of the Act and were not in the United States. During the ~~three-month~~six ~~period~~months ended ~~August~~November 3130, 2025, the Company issued a total of ~~375~~750,000 shares to Rain Communications, which were valued at $~~120~~250,000. ~~Subsequent~~based toon ~~August 31, 2025,~~ the ~~Company~~fair ~~issued~~value aof ~~further~~services ~~125~~received,~~000~~ ~~shares~~consistent towith ~~Rain~~ASC ~~Communications, valued at $33,750~~718.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit
Number		Description of Document
3.1		Articles of Incorporation (2)
3.2		Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.(3)
3.3		Articles of Merger - Stimcell Energetics Inc. and Sports Asylum, Inc.(3)
3.4		Bylaws (1)
3.5		Certificate of Change - Decrease in Authorized Capital from 7,500,000,000 shares of common stock, par value $0.001, to 500,000,000 shares of common stock, par value, $0.001 and corresponding decrease in the issued shares of common stock (18)
3.6		Certificate of Amendment - Change of Name to “Stimcell Energetics Inc.” and Restatement of Articles of Incorporation(18)
4.1		Specimen Stock Certificate (1)
10.1		Distribution Agreement between Stimcell Energetics Inc. and Live Current Media, Inc., dated for reference March 21, 2019. (4)
10.2		Buyback agreement between Live Current Media Inc. and Stimcell Energetics Inc., dated January 29, 2020.(5)
10.3		Loan Agreement dated July 3, 2020, among Stimcell Energetics Inc. and David Jeffs. (6)
10.4		Loan Agreement and Note Payable dated November 30, 2020, among Stimcell Energetics Inc. and Tradex Capital Corp.(6)
10 .5		Loan Agreement and Note Payable dated December 14, 2020, among Cell MedX (Canada) Corp. and Richard Jeffs.(7)
10.6		Loan Agreement and Note Payable dated December 23, 2020, among Cell MedX (Canada) Corp. and Richard Jeffs.(7)
10 .7		Loan Agreement and Note Payable dated March 29, 2021, among Cell MedX (Canada) Corp. and Susan Jeffs.(8)
10.8		Loan Agreement and Note Payable dated October 15, 2021, among Stimcell Energetics Inc. and Richard Jeffs.(8)
10.9		Loan Agreement and Note Payable dated May 18, 2021, among Stimcell Energetics Inc. and Richard Jeffs.(8)
10 .10		Loan Agreement and Note Payable dated June 22, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs.(8)
1 0 .11		Loan Agreement and Note Payable dated October 7, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs.(9)
1 0 .12		Loan Agreement and Note Payable dated October 26, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (9)
10.13		Loan Agreement and Note Payable dated November 24, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (9)
10 .14		Loan Agreement and Note Payable dated November 29, 2021, among Stimcell Energetics Inc. and Bradley Hargreaves. (9)
10.15		Loan Agreement and Note Payable dated December 30, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (10)
10.16		Loan Agreement and Note Payable dated January 27, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (10)

Exhibit
Number		Description of Document
10.17		Loan Agreement and Note Payable dated February 24, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (10)
10.18		Loan Agreement and Note Payable dated March 29, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (10)
10.19		Loan Agreement and Note Payable dated April 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (12)
10.20		Loan Agreement and Note Payable dated May 31, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (12)
10.21		Loan Agreement and Note Payable dated June 27, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (12)
10.22		Loan Agreement and Note Payable dated July 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (12)
10.23		Loan Agreement and Note Payable dated October 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(11)
10.24		Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (11)
10.25		Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (11)
10.26		Loan Agreement and Note Payable dated October 11, 2022, among Stimcell Energetics Inc. and Richard Jeffs. (11)
10.27		Loan Agreement and Note Payable dated October 11, 2022, among Stimcell Energetics Inc. and Richard Jeffs. (11)
10.28		Loan Agreement dated September 2, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
10.29		Loan Agreement dated September 6, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
10.30		Loan Agreement dated November 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
10.31		Loan Agreement dated November 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
10.32		Loan Agreement dated December 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
10.33		Loan Agreement dated January 24, 2023, among Stimcell Energetics Inc. and David Jeffs.(12)
10.34		Loan Agreement dated January 24, 2023, among Stimcell Energetics Inc. and Amir Vahabzadeh.(12)
10.35		Loan Agreement dated January 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
10.36		Loan Agreement dated April 11, 2023, among Stimcell Energetics Inc. and Amir Vahabzadeh. (13)
10.37		Loan Agreement dated April 25, 2023, among Stimcell Energetics Inc. and David Jeffs. (13)
10.38		Loan Agreement dated May 16, 2023, among Stimcell Energetics Inc. and Amir Vahabzadeh. (14)
10.39		Loan Agreement dated May 18, 2023, among Stimcell Energetics Inc. and Sam Ahdoot.(14)
10.40		Loan Agreement dated January 4, 2024, among Stimcell Energetics Inc. and Amir Vahabzadeh. (15)
10.41		Loan Agreement dated January 4, 2024, among Stimcell Energetics Inc. and Sam Ahdoot. (15)
10.42		Loan Agreement dated November 12, 2024, among Stimcell Energetics, Inc. and Amir Vahabzadeh.(16)

Exhibit
Number		Description of Document
10.43		Digital marketing services agreement between the Company and Rain Communications Inc. dated March 18, 2025.(17)
10.17		Loan Agreement and Note Payable dated February 24, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (10)
10.44		Debt settlement agreement dated March 24, 2025.(17)
10.18		Loan Agreement and Note Payable dated March 29, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (10)
10.45		Line of credit agreement dated February 14, 2025, among Stimcell Energetics Inc. and Richard Jeffs (19)
10.19		Loan Agreement and Note Payable dated April 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (12)
10.46		Line of credit agreement dated February 14, 2025, among Stimcell Energetics Inc. and Susan Jeffs(19)
10.20		Loan Agreement and Note Payable dated May 31, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (12)
10.47		Loan Agreement dated March 20, 2025, among Stimcell Energetics Inc. and David Jeffs. (20)
10.21		Loan Agreement and Note Payable dated June 27, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (12)
10.48		Loan Agreement dated March 25, 2025, among Stimcell Energetics Inc. and Amir Vahabzadeh. (20)
10.22		Loan Agreement and Note Payable dated July 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (12)
10.49		Line of credit agreement dated June 20, 2025, among Stimcell Energetics Inc. and Richard Jeffs(20)
10.23		Loan Agreement and Note Payable dated October 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(11)
10.50		Amendment to the line of credit agreement dated July 21, 2025, among Stimcell Energetics Inc. and Richard Jeffs(20)
10.24		Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (11)
31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10.25		Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (11)
31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
10.26		Loan Agreement and Note Payable dated October 11, 2022, among Stimcell Energetics Inc. and Richard Jeffs. (11)
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
10.27		Loan Agreement and Note Payable dated October 11, 2022, among Stimcell Energetics Inc. and Richard Jeffs. (11)
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
10.28		Loan Agreement dated September 2, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
101		The following materials from this Quarterly Report on Form 10-Q for the three months ended August 31, 2025 and 2024 formatted in iXBRL (extensible Business Reporting Language):
10.29		Loan Agreement dated September 6, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
		(1) Unaudited Condensed Consolidated Balance Sheets at August 31, 2025 and as at May 31, 2025.
10.30		Loan Agreement dated November 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
		(2) Unaudited Condensed Consolidated Statements of Operations for the three months ended August 31, 2025 and 2024.
10.31		Loan Agreement dated November 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
		(3) Unaudited Condensed Consolidated Statement of Stockholders’ Deficit as at August 31, 2025 and 2024.
10.32		Loan Agreement dated December 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
		(4) Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended August 31, 2025 and 2024.
10.33		Loan Agreement dated January 24, 2023, among Stimcell Energetics Inc. and David Jeffs.(12)
10.34		Loan Agreement dated January 24, 2023, among Stimcell Energetics Inc. and Amir Vahabzadeh.(12)
10.35		Loan Agreement dated January 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(12)
10.36		Loan Agreement dated April 11, 2023, among Stimcell Energetics Inc. and Amir Vahabzadeh. (13)
10.37		Loan Agreement dated April 25, 2023, among Stimcell Energetics Inc. and David Jeffs. (13)
10.38		Loan Agreement dated May 16, 2023, among Stimcell Energetics Inc. and Amir Vahabzadeh. (14)
10.39		Loan Agreement dated May 18, 2023, among Stimcell Energetics Inc. and Sam Ahdoot.(14)
10.40		Loan Agreement dated January 4, 2024, among Stimcell Energetics Inc. and Amir Vahabzadeh. (15)
10.41		Loan Agreement dated January 4, 2024, among Stimcell Energetics Inc. and Sam Ahdoot. (15)
10.42		Loan Agreement dated November 12, 2024, among Stimcell Energetics, Inc. and Amir Vahabzadeh.(16)

Exhibit
Number		Description of Document
10.43		Digital marketing services agreement between the Company and Rain Communications Inc. dated March 18, 2025.(17)
10.44		Debt settlement agreement dated March 24, 2025.(17)
10.45		Line of credit agreement dated February 14, 2025, among Stimcell Energetics Inc. and Richard Jeffs (19)
10.46		Line of credit agreement dated February 14, 2025, among Stimcell Energetics Inc. and Susan Jeffs(19)
10.47		Loan Agreement dated March 20, 2025, among Stimcell Energetics Inc. and David Jeffs. (20)
10.48		Loan Agreement dated March 25, 2025, among Stimcell Energetics Inc. and Amir Vahabzadeh. (20)
10.49		Line of credit agreement dated June 20, 2025, among Stimcell Energetics Inc. and Richard Jeffs(20)
10.50		Amendment to the line of credit agreement dated July 21, 2025, among Stimcell Energetics Inc. and Richard Jeffs(20)
31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101		The following materials from this Quarterly Report on Form 10-Q for the three and six months ended November 30, 2025 and 2024 formatted in iXBRL (extensible Business Reporting Language):
		(1) Unaudited Condensed Consolidated Balance Sheets at November 30, 2025 and as at May 31, 2025.
		(2) Unaudited Condensed Consolidated Statements of Operations for the three and six months ended November 30, 2025 and 2024.
		(3) Unaudited Condensed Consolidated Statement of Stockholders’ Deficit as at November 30, 2025 and 2024.
		(4) Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended November 30, 2025 and 2024.

(1)Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC on July 13, 2010

(2)Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010

(3)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014

(4)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 27, 2019

(5)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 31, 2020

(6)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 15, 2020

(7)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 9, 2021

(8)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on August 30, 2021

(9)Filed as an exhibit to the Company’s Annual Report on Form 10-Q filed with the SEC on January 12, 2022

(10)Filed as an exhibit to the Company’s Annual Report on Form 10-Q filed with the SEC on April 11, 2022

(11)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 18, 2022

(12)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on April 7, 2023

(13)Filed as an exhibit to the Company’s Annual Report on Form 10-Q filed with the SEC on May 19, 2023

(14)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on June 29, 2023

(15)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 15, 2024

(16)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2025

(17)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 28, 2025

(18)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2024

(19)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2025

(20)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 2, 2025

1011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Stimcell Energetics Inc.
Date: October 14, 2025	By:	/s/ David Jeffs
Date: January 15, 2026	By:	/s/ David Jeffs
		David Jeffs
		Chief Executive Officer and Director
		(Principal Executive Officer)
Date: October 14, 2025	By:	/s/Yanika Silina
Date: January 15, 2026	By:	/s/Yanika Silina
		Yanika Silina
		Chief Financial Officer
		(Principal Accounting Officer)

1112

Filing Compare · Stimcell Energetics Inc.